 The current study is a prospective, randomized, open, multi-center investigation. The aim of current study is to investigate whether the HBsAg clearance rate can be improved if applying RGT strategy in HBeAg positive CHB patients treated by NUC achieved HBVDNA1000copiesml,and HBsAg5000IUml; HBeAg100PEIUml or470sco, combined with PEG-IFN a-2a for 24 weeks. Then the subjects will be divided into three groups according to qHBsAg levels of week 24 RGT. For the subjects who qHBsAg200IUml of week 24, they are defined in Group A; the subjects in Group A will continue to be treated by NUC combined with PEG-IFN a-2a 180μg for another 24 weekstotal will be 48 weeks. If the qHBsAg at week 24 did not achieve minor 200IUml, the subjects will be randomized to 2 groups: Group B: the subjects will continue to be treated by NUC combined with PEG-IFN a-2a 180μg for another 24 weeks total will be 48 weeks; Group C: the subjects will be treated by NUC until 48 weeks. 